Notification about latest news from us.
Pfizer secures a $10 billion acquisition of Metsera, concluding a heated bidding war against Novo Nordisk.
TrumpRx aims to reduce prescription medication costs for Americans but faces skepticism over its potential effectiveness.
Singapore's pharmaceutical companies seek exemption clarity from new US tariffs, signaling potential impacts on $3.1 billion exports.
Trump's latest tariffs target pharmaceuticals, furniture, and trucks, imposing steep duties to bolster U.S. manufacturing starting October 1.
Trump's plan to impose 200% tariffs on imported drugs could lead to higher prices and shortages for consumers.
The US expects to generate $50 billion in monthly tariff revenues as new import levies begin to take effect.
Trump announces potential tariffs on pharmaceuticals, threatening rates up to 250% to boost domestic manufacturing.
Indonesia's military will start manufacturing medicines for civilian use, raising concerns about increased military powers and potential authoritarianism.
AstraZeneca plans a $50 billion investment in U.S. manufacturing, influenced by Trump's upcoming tariffs on imports.
Novartis' new malaria treatment for infants, Coartem Baby, has received approval, aiming to reduce malaria's devastating impact on young children.
By clicking send you'll receive occasional emails from newsletters about this topic.